This miracle drug, Inclisiran reduces bad Cholesterol levels in patients by 51% in 1 month of administering the drug

There is seriously a good news from researchers at Imperial College London to the people suffering from high cholesterol and cardiovascular diseases. Scientists from Imperial College London have discovered a drug that can reduce the bad cholesterol by a whopping 51% in less than one month of administering the drug and that too without no side effects.

Cardiovascular diseases are becoming more common these days in many developed and developing countries due to change in lifestyle which replaced the healthy diet with junk food that contains a lot of bad cholesterol.

Also read: Researchers find that obese people exercising in middle age reduce the risk of heart attack or stroke irrespective of body mass Index (BMI)

Patients suffering from cardiovascular diseases due to higher accumulation of Low-density Lipoprotein (LDL) Cholesterol are administered with Statins, a drug that reduces the LDL Cholesterol when administered regularly. This drug to function effectively have to be taken regularly without missing any single day. If the patient fails to take the drug, the cholesterol levels rise to some extent making him vulnerable to the cardiovascular or heart diseases. Statins are to be given in higher doses to function effectively, while some patients remain intolerable to the higher doses. These downsides make Statins an ineffective treatment to reduce higher Cholesterol levels.


This miracle drug, Inclisiran reduces bad Cholesterol levels in patients by 51% in 1 month of administering the drug


The new drug called Inclisiran could help to reduce the risk of heart attacks and stroke related to high cholesterol. Now, in phase 2 clinical trial, it has confirmed the effectiveness of injecting inclisiran for reducing cholesterol that can be taken alone or potentially combined with statins for maximum effect.


The researchers found that just one month after receiving a single treatment of inclisiran, patients' LDL cholesterol levels had reduced by up to 51 percent.

The drug works on the technique called RNA interference (RNAi) therapy which essentially 'switches off' one of the genes responsible for elevated cholesterol.

No comments:

Powered by Blogger.